Premium
Rifampicin and vitamin D metabolism
Author(s) -
Brodie M J,
Boobis A R,
Dollery C T,
Hillyard Carmel J,
Brown D J,
Maclntyre I,
Park B K
Publication year - 1980
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1980.115
Subject(s) - osteomalacia , calcitonin , rifampicin , endocrinology , parathyroid hormone , medicine , vitamin d and neurology , clinical pharmacology , metabolism , drug , chemistry , pharmacology , calcium , antibiotics , biochemistry
A 2‐wk course of rifampicin orally (600 mg/day) in 8 male subjects resulted in a consistent fall in plasma 25‐hydroxycholecalciferol (25‐OHD) levels of around 70%, accompanied by increased oxidation of antipyrine and 6β‐hydroxycortisol (indicative of hepatic enzyme induction). Plasma levels of 1,25‐dihydroxycholecalciferol, parathyroid hormone, and calcitonin were not altered. The fall in 25‐OHD may represent the earliest lesion of drug‐induced osteomalacia. Clinical Pharmacology and Therapeutics (1980) 27 , 810–814; doi: 10.1038/clpt.1980.115